Сравнение
Gonadorelin vs. Linaclotid
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Исследования (прочее)
Исследования (прочее)
Номер CAS
33515-09-2
851199-59-2
Молекулярная масса
1182.29 g/mol
1526.74 g/mol
Период полувыведения
0.1 h
нет данных
Последовательность
pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2нет данных
Механизм действия
Gonadorelin
Gonadorelin acts as an agonist at the GnRH receptor on the gonadotroph cells of the pituitary and triggers release of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The temporal pattern of receptor exposure is decisive: pulsatile administration mimics the natural hypothalamic secretory rhythm and sustains LH/FSH release, whereas continuous exposure leads to receptor internalisation and desensitisation with subsequent paradoxical suppression of gonadotropins. The latter principle is exploited therapeutically by longer-acting GnRH agonists.
Linaclotid
Linaclotide activates the guanylate cyclase-C receptor on the luminal surface of the intestinal epithelium. This raises cyclic GMP (cGMP), increases secretion of chloride and bicarbonate into the lumen, raises stool fluid content and accelerates transit; pain signaling is also modulated.
Доказательная база
Наивысшая доказательность
Исследование на людях
РКИ на людях
Исследования
4
0
из них на людях
4
0
Зафиксированные эффекты
4
2
Открытые противоречия
1
0
Задокументированные нежелательные явления
2
1
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Gonadorelin and Linaclotid?
- Gonadorelin is classified as "Исследования (прочее)", while Linaclotid is classified as "Исследования (прочее)". Gonadorelin: Gonadorelin is the synthetic decapeptide with an amino-acid sequence identical to endogenous gonadotropin-releasing hormone (GnRH/LHRH). Historically approved in several countries for diagnostic testing of pituitary function and for fertility indications (pump systems). A defining feature is the opposite effect of pulsatile versus continuous administration: pulsatile stimulates, continuous leads to receptor desensitisation. Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Gonadorelin or Linaclotid?
- The highest available evidence level is "Исследование на людях" for Gonadorelin and "РКИ на людях" for Linaclotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Gonadorelin and Linaclotid in Germany and the United States?
- Германия: Gonadorelin — Рецептурный, Linaclotid — Рецептурный. США: Gonadorelin — Рецептурный, Linaclotid — Рецептурный. These are factual summaries with source and review date on the individual pages.